Targeting <i>APOC3</i> with Olezarsen in Moderate Hypertriglyceridemia
Among patients with moderate hypertriglyceridemia and elevated cardiovascular risk, treatment with olezarsen resulted in significantly greater reduction in triglyceride levels at 6 months than placebo. (Funded by Ionis Pharmaceuticals; ESSENCE-TIMI 73b ClinicalTrials.gov number, NCT05610280.).
Authors
- Thomas A Prohaska (ORCID: https://orcid.org/0000-0002-1406-692X)
- Erica L. Goodrich (ORCID: https://orcid.org/0000-0002-8541-264X)
- Marc S. Sabatine (ORCID: https://orcid.org/0000-0002-0691-3359)
- Robert P. Giugliano (ORCID: https://orcid.org/0000-0003-4110-7675)
- Maciej Banach (ORCID: https://orcid.org/0000-0001-6690-6874)
- Brian A. Bergmark (ORCID: https://orcid.org/0000-0003-4360-7606)
- Michael T. Lu (ORCID: https://orcid.org/0000-0003-4696-9610)
- Filipe A. Moura (ORCID: https://orcid.org/0000-0001-8017-1675)
- S. M. Zhang
- Veronica J. Alexander (ORCID: https://orcid.org/0000-0003-3729-5749)
- André Zimerman (ORCID: https://orcid.org/0000-0001-8977-6929)
- Sabina A. Murphy (ORCID: https://orcid.org/0000-0002-8231-3611)
- Sotirios Tsimikas (ORCID: https://orcid.org/0000-0001-9834-9494)
- Nicholas Marston (ORCID: https://orcid.org/0000-0001-6164-4617)
- Julia Weinland
- Dan Li (ORCID: https://orcid.org/0000-0002-1264-5952)
- Yu Mi Kang (ORCID: https://orcid.org/0000-0002-6272-0666)
Institutions
- Brigham and Women's Hospital (US)
- Harvard University (US)
- Ionis Pharmaceuticals (United States) (US)
- Yale University (US)
- University of California San Diego (US)
- Hospital Moinhos de Vento (BR)
- VA Connecticut Healthcare System (US)
- Massachusetts General Hospital (US)
- Medical University of Lodz (PL)
- Amsterdam University Medical Centers (NL)
- Thrombolysis in Myocardial Infarction Study Group (US)
Publication Details
- Journal
- New England Journal of Medicine
- Published
- 2025-08-30
- DOI
- https://doi.org/10.1056/nejmoa2507227
- Citations
- 32
- Primary Topic
- Lipid metabolism and disorders
- Type
- article
- Field-Weighted Citation Impact
- 44.42
Funders
- Ionis Pharmaceuticals